Drug Profile


Alternative Names: IDD-3; Melanoma vaccine - IDM Pharma; Uvidem

Latest Information Update: 22 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDM Pharma
  • Developer Takeda America Holdings
  • Class Antineoplastics; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 25 Jun 2009 IDM Pharma has been acquired and merged into Takeda America Holdings
  • 25 Jun 2009 IDM Pharma has been acquired by Takeda America Holdings
  • 06 Nov 2007 Updated results from a phase II clinical trial (DC-MEL-202) in patients with advanced melanoma added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top